Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: An overview

Medical Science Monitor

Volumn 22, Issue , 2016, Pages 2501-2512

  Chen, Changyi Johnny ^a   Lü, Jian Ming ^a   Yao, Qizhi ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular diseases; Gout; Hyperuricemia

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; GLUCOSE TRANSPORTER; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; URATE TRANSPORTER; URIC ACID; XANTHINE OXIDASE; ENZYME INHIBITOR; XANTHINE DEHYDROGENASE;

ANTIOXIDANT ASSAY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIETARY INTAKE; ENZYME ACTIVITY; ENZYME INHIBITION; GOUT; HUMAN; HYDROXYLATION; HYPERTENSION; HYPERURICEMIA; HYPOURICEMIA; INFLAMMATION; MOLECULAR PATHOLOGY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; XANTHINURIA; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; METABOLISM; RISK FACTOR;

ALLOPURINOL; ANIMALS; ENZYME INHIBITORS; FEBUXOSTAT; HUMANS; HYPERURICEMIA; REACTIVE OXYGEN SPECIES; RISK FACTORS; XANTHINE DEHYDROGENASE;

EID: 84983395255     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.899852     Document Type: Review

References (117)

1. Galassi FM, Borghi C: A brief history of uric acid: from gout to cardiovascular risk factor. Eur J Intern Med, 2015; 26: 373
2. Li M, Hu X, Fan Y et al: Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta- analysis. Sci Rep, 2016; 6: 19520
3. Braga F, Pasqualetti S, Ferraro S, Panteghini M: Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: A systematic review and meta-analysis. Clin Chem Lab Med, 2016; 54(1): 7–15
4. Borghi C, Desideri G. Urate-lowering drugs and prevention of cardiovascular disease: The emerging role of xanthine oxidase inhibition. Hypertension, 2016; 67(3): 496–98
5. Chauhan M, Kumar R: A comprehensive review on bioactive fused heterocycles as purine-utilizing enzymes inhibitors. Med Chem Res, 2015; 24: 2259–82
6. Scheele C: Examen chemicum calculi urinari. Opuscula, 1776; 2: 73
7. Kippen I, Klinenberg J R, Weinberger A, Wilcox WR: Factors affecting urate solubility in vitro. Ann Rheum Dis, 1974; 33: 313–17
8. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep, 2012; 14(2): 179–88
9. Desideri G, Castaldo G, Lombardi A et al: Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci, 2014; 18(9): 1295–306
10. Khanna D, FitzGerald JD, Khanna PP et al: American College of Rheumatology Guidelines for Management of Gout Part I: Systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia, Arthritis Care Res (Hoboken), 2012; 64(10): 1431–46
11. Hille R, Nishino T: Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase. FASEB J, 1995; 9: 995–1003
12. Hille R, Nishino T, Bittner F. Molybdenum enzymes in higher organisms. Coord Chem Rev, 2011; 255: 1179–205
13. Hellsten-Westing Y: Immunohistochemical localization of xanthine oxidase in human cardiac and skeletal muscle. Histochemistry, 1993; 100: 215–22
14. Cejková J, Ardan T, Filipec M, Midelfart A. Xanthine oxidoreductase and xanthine oxidase in human cornea. Histol Histopathol, 2002; 17(3): 755–60
15. Linder N, Rapola J, Raivio KO: Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Investig, 1999; 79: 967–74
16. Enroth C, Eger BT, Okamoto K et al: Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: Structure-based mechanism of conversion. Proc Natl Acad Sci USA, 2000; 97: 10723–28
17. Battelli MG, Bolognesi A, Polito L: Pathophysiology of circulating xanthine oxidoreductase: New emerging roles for a multi-tasking enzyme. Biochim Biophys Acta, 2014; 1842(9): 1502–17
18. Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum, 2011; 63: 3136–41
19. Kratzer JT, Lanaspa MA, Murphy MN et al: Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci USA, 2014; 111(10): 3763–68
20. Proctor P: Similar functions of uric acid and ascorbate in man? Nature, 1970; 228: 868
21. Watanabe S, Kang Dh, Feng L et al: Uric acid, hominoid evolution, and the pathogenesis of saltsensitivity. Hypertension, 2002; 40: 355–60
22. Inouye E, Park KS, Asaka A: Blood uric acid level and IQ: A study in twin families. Acta Genet Med Gemellol (Roma), 1984; 33: 237–42
23. Shi Y, Evans JE, Rock K: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 2003; 425: 516–21
24. Grassi D, Ferri L, Desideri G et al: Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des, 2013; 19: 2432–38
25. Liu R, Han C, Wu D et al: Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: A systematic review and meta-analysis. Biomed Res Int, 2015; 2015: 762820
26. Michelis MF, Warms PC, Fusco RD, Davis BB: Hypouricemia and hyperuricosuria in Laennec cirrhosis. Arch Intern Med, 1974; 134: 681–83
27. Levartovsky D, Lagziel A, Sperling O et al: XDH gene mutation is the underlying cause of classical xanthinuria: A second report. Kidney Int, 2000; 57: 2215–20
28. Windpessl M, Ritelli M, Wallner M, Colombi M: A novel homozygous SLC2A9 mutation associated with renal-induced hypouricemia. Am J Nephrol, 2016; 43(4): 245–50
29. Kim HO, Ihm CG, Jeong KH et al: A case report of familial renal hypouricemia confirmed by genotyping of SLC22A12, and a literature review. Electrolyte Blood Press, 2015; 13(2): 52–57
30. Sundy JS, Becker MA, Baraf HS et al., Pegloticase Phase 2 Study Investigators: Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment- failure gout: results of a phase II randomized study. Arthritis Rheum, 2008; 58: 2882
31. Kuo CF, Grainge MJ, Zhang W, Doherty M: Global epidemiology of gout: Prevalence, incidence and risk factors. Nat Rev Rheumatol, 2015; 11(11): 649–62
32. Roddy E, Zhang W, Doherty M: The changing epidemiology of gout. Nat Clin Pract Rheumatol, 2007; 3: 443–49
33. Chou CT, Lai JS: The epidemiology of hyperuricaemia and gout in Taiwan aborigines. Br J Rheumatol, 1998; 37(3): 258–62
34. Katsiki N, Karagiannis A, Athyros VG, Mikhailidis DP: Hyperuricaemia: More than just a cause of gout? J Cardiovasc Med, 2013; 14: 397–402
35. Storhaug HM, Norvik JV, Toft I et al: Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: A gender specific analysis from The Tromsø Study. BMC Cardiovasc Disord, 2013; 13: 115
36. Zalawadiya SK, Veeranna V, Mallikethi-Reddy S et al: Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol, 2015; 22(4): 513–18
37. Yuan H, Yu C, Li X et al: Serum uric acid levels and risk of metabolic syndrome: A dose-response meta-snalysis of prospective studies. J Clin Endocrinol Metab, 2015; 100(11): 4198–207
38. Shih MH, Lazo M, Liu SH et al: Association between serum uric acid and nonalcoholic fatty liver disease in the US population. J Formos Med Assoc, 2015; 114(4): 314–20
39. Dubreuil M, Zhu Y, Zhang Y et al: Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis, 2015; 74: 1368–72
40. MacIsaac RL, Salatski J, Higgins P et al: Allopurinoil and cardiovascular outcomes in adultes with hypertension. Hypertension, 2016; 67: 535–40
41. Kanbay M, Jensen T, Solak Y et al: Uric acid in metabolic syndrome: From an innocent bystander to a central player. Eur J Intern Med, 2016; 29: 3–8
42. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev, 2007; 87(1): 315–424
43. Chen AY, Lü JM, Yao Q, Chen C: Entacapone is an antioxidant more potent than vitamin C and vitamin E for scavenging of hypochlorous acid and peroxynitrite, and the inhibition of oxidative stress-induced cell death. Med Sci Monit, 2016; 22: 687–96
44. Panasenko OM, Evgina SA, Driomina ES et al: Hypochlorite induces lipoproteins and lipid peroxidation in blood phospholipid liposomes. Free Radic Biol Med, 1995; 19: 133–40
45. Radi R, Beckman JS, Bush KM, Freeman BA: Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys, 1991; 288(2): 481–87
46. Ogino K, Kato M, Furuse Y et al: Uric acid-lowering treatment with benzbromarone in patients with heart failure: A double-blind placebo-controlled crossover preliminary study. Circ Heart Fail, 2010; 3(1): 73–81
47. Minhas KM, Saraiva RM, Schuleri KH et al: Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res, 2006; 98(2): 271–79
48. Pritsos CA: Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact, 2000; 129(1–2): 195–208
49. Radi R, Rubbo H, Bush K, Freeman BA: Xanthine oxidase binding to glycosaminoglycans: Kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparin complexes. Arch Biochem Biophys, 1997; 339: 125–35
50. Khosla UM, Zharikov S, Finch JL et al: Hyperuricemia induces endothelial dysfunction. Kidney Int, 2005; 67(5): 1739–42
51. George J. Carr E, Davies J et al: High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation, 2006; 114(23): 2508–16
52. Warning WS: Uric acid: An important antioxidant in acute ischaemic stroke, QJM, 2002; 95: 691–93
53. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA, 1981; 78: 6858–62
54. Skinner KA, White CR, Patel R et al: Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J Biol Chem, 1998; 273(38): 24491–97
55. Ghio AJ, Kennedy TP, Stonehuerner J et al: Iron regulates xanthine oxidase activity in the lung. Am J Physiol, 2002; 283: L563–72
56. Muraoka S, Miura T: Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol Toxicol, 2003; 93: 284–89
57. Bagnati M, Perugini C, Cau C et al: When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: A study using uric acid. Biochem J, 1999; 340: 143–52
58. Enomoto A, Kimura H, Chairoungdua A et al: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature, 2002; 417 (6887): 447–52
59. Weir CJ, Muir SW, Walters MR, Lees KR: Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke, 2003; 34: 1951–56
60. Ruggiero C, Cherubini A, Ble A et al: Uric acid and inflammatory markers. Eur Heart J, 2006; 27(10): 1174–81
61. Choi YJ, Yoon Y, Lee KY et al: Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J, 2014; 28(7): 3197–204
62. Li P, Zhang L, Zhang M et al: Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: A mechanism for uric acid-induced endothelial dysfunction. Int J Mol Med, 2016; 37(4): 989–97
63. Skinner KA, White CR, Patel R et al: Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J Biol Chem, 1998; 273: 24491–97
64. Rosen ED, Spiegelman BM: Molecular regulation of adipogenesis. Annu RevCell Dev Biol, 2000; 16: 145–71
65. Martyn KD, Frederick LM, von Loehneysen K et al: Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal, 2006; 18: 69–82
66. Cicerchi C, Li N, Kratzer J et al: Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: Evolutionary implications of the uricase loss in hominids. FASEB J, 2014; 28(8): 3339–50
67. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ: Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/ nitrosative stress. Am J Physiol Cell Physiol, 2007; 293(2): C584–96
68. Zhang Y, Yamamoto T, Hisatome I et al: Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic b cells. Mol Cell Endocrinol, 2013; 375: 89–96
69. Rao GN, Corson MA, Berk BC: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem, 1991; 266(13): 8604–8
70. Han HJ, Lim MJ, Lee YJ et al: Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB. Am J Physiol Renal Physiol, 2007; 292: F373–81
71. Pacher P, Nivorozhkin A, Szabó C: Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol Rev, 2006; 58(1): 87–114
72. Okamoto K, Eger BT, Nishino T et al: Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol. Nucleosides Nucleotides Nucleic Acids, 2008; 27(6): 888–93
73. Grimaldi-Bensouda L, Alpérovitch A, Aubrun E et al., PGRx MI Group: Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis, 2014; 103: 51–57
74. Struthers A, Shearer F: Allopurinol: novel indications in cardiovascular disease. Heart, 2012; 98(21): 1543–45
75. McInnes GT, Lawson DH, Jick H: Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis, 1981; 40: 245–49
76. Aubock J, Fritsch P: Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. Br Med J, 1985; 290: 1969–70
77. Lin MS, Dai YS, Pwu RF et al: Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J, 2005; 35(3): 188–90
78. Yaylacı S, Demir MV, Temiz T et al: Allopurinol-induced DRESS syndrome. Indian J Pharmacol, 2012; 44(3): 412–14
79. Mockenhaupt M, Viboud C, Dunant A et al: Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: The EuroSCAR-study. J Invest Dermatol, 2008; 128: 35–44
80. Ramasamy SN, Korb-Wells CS, Kannangara DR et al: Allopurinol hypersensitivity: A systematic review of all published cases, 1950-2012. Drug Saf, 2013; 36: 953–80
81. Lee MH, Stocker SL, Anderson J et al: Initiating allopurinol therapy: Do we need to know the patient’s human leucocyte antigen status? Intern Med J, 2012; 42(4): 411–16
82. Hassan S, Wetz R, Zouein E: Allopurinol causing drug rash with eosinophilia and sysyrmic symptoms syndrome: A challenging diagnosis. Int J Gen Med, 2011; 4: 789–92
83. Burns CM, Wortmann RL: Gout therapeutics: new drugs for an old disease. Lancet, 2011; 377(9760): 165–77
84. Love BL, Barrons R, Veverka A, Snider KM: Urate-lowering therapy for gout: Focus on febuxostat, Pharmacotherapy, 2010; 30: 594–608
85. Calogiuri G, Nettis E, Di Leo E et al: Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules. Inflamm Allergy Drug Targets, 2013; 12: 19–28
86. Chohan S: Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol, 2011; 38: 1957–59
87. Abeles AM: Febuxostat hypersensitivity. J Rheumatol, 2012; 39: 659
88. Schumacher HR Jr., Becker MA, Wortmann RL et al: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum, 2008; 59(11): 1540–48
89. www.accessdata.fda.gov. Accessed April 27, 2016
90. Mauck M, Taintor A, Jha P: Cross-sensitivity of allopurinol and febuxostatinduced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. J Gen Intern Med, 2010; 25: S504–5
91. Bardin T, Chalès G, Pascart T et al: Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine, 2016; 83(3): 314–17
92. Bohm M, Vuppalanchi R, Chalasani N, Drug-Induced Liver Injury Network (DILIN): Febuxostat-induced acute liver injury. Hepatology, 2016; 63(3): 1047–49
93. Kang Y, Kim MJ, Jang HN et al: Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease. J Clin Pharm Ther, 2014; 39(3): 328–30
94. Hosoya T, Sasaki T, Hashimoto H et al: Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: An exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. J Clin Pharm Ther, 2016; 41(3): 298–305
95. Matsumoto K, Okamoto K, Ashizawa N, Nishino T: FYX-051: A novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther, 2011; 336(1): 95–103
96. Rodrigues MV, Barbosa AF, da Silva JF et al: 9-Benzoyl 9-deazaguanines as potent xanthine oxidase inhibitors. Bioorg Med Chem, 2016; 24(2): 226–31
97. Nepali K, Agarwal A, Sapra S et al: N-(1,3-Diaryl-3-oxopropyl)amides as a new template for xanthine oxidase inhibitors. Bioorg Med Chem, 2011; 19(18): 5569–76
98. Kumar D, Kaur G, Negi A et al: Synthesis and xanthine oxidase inhibitory activity of 5,6-dihydropyrazolo/pyrazolo[1,5-c]quinazoline derivatives. Bioorg Chem, 2014; 57: 57–64
99. Sharma S, Sharma K, Ojha R et al: Microwave assisted synthesis of naphthopyrans catalysed by silica supported fluoroboric acid as a new class of non-purine xanthine oxidase inhibitors. Bioorg Med Chem Lett, 2014; 24(2): 495–500
100. Sathisha KR, Gopal S, Rangappa KS: Antihyperuricemic effects of thiadiazolopyrimidin- 5-one analogues in oxonate treated rats. Eur J Pharmacol, 2016; 776: 99–105
101. Sun ZG, Zhou XJ, Zhu ML et al: Synthesis and biological evaluation of novel aryl-2H-pyrazole derivatives as potent non-purine xanthine oxidase inhibitors. Chem Pharm Bull (Tokyo), 2015; 63(8): 603–7
102. Smelcerovic Z, Veljkovic A, Kocic G et al: Xanthine oxidase inhibitory properties and anti-inflammatory activity of 2-amino-5-alkylidene-thiazol-4-ones. Chem Biol Interact, 2015; 229: 73–81
103. Song JU, Choi SP, Kim TH et al: Design and synthesis of novel 2-(indol-5-yl) thiazole derivatives as xanthine oxidase inhibitors. Bioorg Med Chem Lett, 2015; 25(6): 1254–58
104. Chen S, Zhang T, Wang J et al: Synthesis and evaluation of 1-hydroxy/methoxy- 4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as nonpurine xanthine oxidase inhibitors. Eur J Med Chem, 2015;103: 343–53
105. Xu F, Zhao X, Yang L et al: A new cycloartane-type triterpenoid saponin xanthine oxidase inhibitor from Homonoia riparia Lour. Molecules, 2014; 19(9): 13422–31
106. Lin S, Zhang G, Pan J, Gong D: Deciphering the inhibitory mechanism of genistein on xanthine oxidase in vitro. J Photochem Photobiol B, 2015; 153: 463–72
107. Zhang J, Shuai X, Li J et al: Biodistribution, hypouricemic efficacy and therapeutic mechanism of morin phospholipid complex loaded self-nanoemulsifying drug delivery systems in an experimental hyperuricemic model in rats. J Pharm Pharmacol, 2016; 68(1): 14–25
108. Shen L, Ji HF: Insights into the inhibition of xanthine oxidase by curcumin. Bioorg Med Chem Lett, 2009; 19(21): 5990–93
109. Masuda T, Shingai Y, Takahashi C et al: Identification of a potent xanthine oxidase inhibitor from oxidation of caffeic acid. Free Radic Biol Med, 2014; 69: 300–7
110. Shi DH, Huang W, Li C et al: Design, synthesis and molecular modeling of aloe-emodin derivatives as potent xanthine oxidase inhibitors. Eur J Med Chem, 2014; 75: 289–96
111. Lü JM, Yao Q, Chen C: 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: A potential therapeutic agent for treatment of hyperuricemia and gout. Biochem Pharmacol, 2013; 86(9): 1328–37
112. Conde E, Cadahía E, García-Vallejo MC, de Simón BF: Polyphenolic composition of quercus suber cork from different spanish provenances. J Agric Food Chem, 1998; 46: 3166–71
113. Lee YS, Kang YH, Jung JY et al: Protein glycation inhibitors from the fruiting body of Phellinus linteus. Biol Pharm Bull, 2008; 31(10): 1968–72
114. Song YS, Kim SH, Sa JH et al: Antiangiogenic, angiogenic, antioxidant and xanthine oxidase inhibition activities of the mushroom Phellinus linteus. J Ethnopharmacol, 2003; 88: 113–16
115. Rao SR, Ravishankar GA: Biotransformation of protocatechuic aldehyde and caffeic acid to vanillin and capsaicin in freely suspended and immobilized cell cultures of Capsicum frutescens. J Biotechnol, 2000; 76(2–3): 137–46
116. Cherniakov I, Domb AJ, Hoffman A: Self-nano-emulsifying drug delivery systems: An update of the biopharmaceutical aspects. Expert Opin Drug Deliv, 2015; 12(7): 1121–33
117. Mazzaferro S, Bouchemal K, Ponchel G: Oral delivery of anticancer drugs III: Formulation using drug delivery systems. Drug Discov Today, 2013; 18: 99–104